GSK Strikes Major Acquisition for Lung Treatments

GSK has announced a significant acquisition, reaching a deal worth $950 million to purchase 35Pharma, a Canadian biopharmaceutical company with a focus on developing therapies for lung diseases linked to obesity. This marks GSK’s second major acquisition since Luke Miels took over as chief executive at the start of the year.

The acquisition includes a promising treatment that has successfully completed early-stage trials. GSK believes this asset, known as HS235, has the potential to become a leading product for various types of pulmonary hypertension (PH). This condition, characterised by high blood pressure in the lungs, can lead to heart failure; treatment options currently available are scarce.

The global market for treatments of pulmonary hypertension is projected to reach $18 billion by the early 2030s, according to analyses by Evaluate Pharma. GSK has indicated that HS235 may offer broader metabolic benefits, including weight loss, which would add additional clinical value in a patient population with high rates of obesity and insulin resistance.

Unlike its competitors in the weight-loss sector, GSK is opting for a strategy that does not involve direct competition in this crowded market. Miels stated that the company aims to explore the downstream effects of obesity, rather than addressing the issue itself directly. This approach has previously led to a notable acquisition where GSK committed up to $2 billion for a treatment targeting liver diseases.

With plans for 15 significant product launches by 2031, GSK aims to achieve key sales growth targets exceeding £40 billion. Analysts estimate that the company may have around £30 billion available for further acquisitions as it continues to strengthen its pipeline.

The deal for 35Pharma follows GSK’s recent acquisition of Rapt Technologies, another clinical-stage company focused on therapies for inflammatory and immunologic diseases. Tony Wood, GSK’s chief scientific officer, remarked on the significant global impact of pulmonary hypertension. He also highlighted that the differentiated profile of HS235 offers new development opportunities within GSK’s existing portfolio.

GSK anticipates that the injection-based medicine could be available to patients by the early 2030s, potentially providing advantages over existing treatments such as Merck’s established drug, Winrevair. This acquisition represents a robust commitment by GSK to innovate in the field of pulmonary health.